The Universal Influenza Vaccine Technology Landscape is a database of novel vaccine candidates designed to provide broader and more durable protection against circulating and pandemic influenza viruses, compared with current strain-specific seasonal influenza vaccines. The landscape encompasses a wide range of investigational technologies that have reached clinical or late preclinical stages of development; some are under active investigation in funded research programs, while others are not in active development. As a research tool, the landscape is intended to facilitate efficient assessment of novel universal influenza vaccine strategies and stimulate informed investments in universal influenza vaccine research and development (R&D) overall.
CIDRAP is developing the landscape with support from the Global Funders Consortium for Universal Influenza Vaccine Development, which was established in 2017 with funding from the Bill and Melinda Gates Foundation. The goal is to compile, curate, and maintain information on universal influenza vaccine technologies and share the information publicly online. As an academic unit operating independently within the University of Minnesota, with no conflicts of interest regarding any influenza vaccine R&D activities or outcomes, CIDRAP serves as a neutral platform for gathering and analyzing influenza vaccine data. CIDRAP is conducting this effort in parallel with the Influenza Vaccines Roadmap initiative, funded by Wellcome Trust.
Advisory Working Group
A small working group was established to provide subject-matter expertise in influenza vaccine R&D and vaccine database development. Joseph Bresee (Task Force for Global Health) and Michael Osterholm (CIDRAP) serve as co-chairs. Members of the group are:
- Martin Friede, World Health Organization (WHO)
- Jennifer Gordon, US National Institute of Allergy and Infectious Diseases (NIAID)
- Deborah Higgins, PATH Center for Vaccine Innovation and Access
- Julia Molto Lopez, European Commission
- Jonathan Seals, US Biomedical Advanced Research and Development Authority (BARDA)
The landscape summarizes data from publicly available sources; no proprietary information is collected. Primary sources of information include:
- Clinical trial registries, such as ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), and the EU Clinical Trials Register
- Peer-reviewed scientific literature, identified via PubMed, Scopus, Google Scholar, and other search tools
- Vaccine industry websites
- Information provided by research sponsors (such as NIAID and BARDA)
CIDRAP will continue to monitor these sources and will update the landscape monthly as new developments emerge. To ensure accuracy and completeness of the database, CIDRAP encourages feedback directly from researchers and developers (see below).
Criteria for Including and Excluding Technologies
The landscape focuses on investigational vaccine technologies in clinical and late preclinical development that are designed to provide broad and durable protection against seasonal influenza A and B viruses and their shifted or drifted variants, including pandemic influenza viruses. The late preclinical stage of development is limited to studies involving experimental animal models. Criteria for identifying appropriate technologies include the following:
- Included are technologies that target conserved epitopes or regions (e.g., the hemagglutinin stem domain) across multiple influenza A virus subtypes or influenza B virus lineages.
- Excluded are technologies that are directed primarily at hypervariable regions of the virus (e.g., in the hemagglutinin head domain), are strain-specific, or use adjuvants as the primary mechanism for broader immunogenicity.
Rows shaded in grey can be expanded by clicking or tapping the + sign tabs at the far left-hand side of the table, or collapsed into a single row per candidate using the – sign tabs.